Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 312
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03580941 | Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy | ||
| NCT03759366 | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) | ||
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT05259085 | Study of ALXN2050 in Participants With Hepatic Impairment | ||
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | ||
| NCT01522170 | aHUS Observational Long Term Follow-Up | ||
| NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | ||
| NCT04660890 | A Study of the Cardiac Effects of ALXN2050 in Healthy Adults | ||
| NCT03310021 | A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects | ||
| NCT02235493 | Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09 | ||
| NCT01757184 | Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency | ||
| NCT05886244 | Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China | ||
| NCT00742859 | Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin | ||
| NCT04543591 | Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant | ||
| NCT04609696 | Study of the Metabolism of Danicopan in Healthy Adults | ||
| NCT04709094 | A Drug Interaction Study of Danicopan | ||
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | ||
| NCT04469465 | Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) | ||
| NCT00838513 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT05047484 | A Study of Multiple Doses of ALXN2050 in Healthy Adults | ||
| NCT05644561 | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis | ||
| NCT04557735 | Study of Ravulizumab in Pediatric Participants With HSCT-TMA | ||
| NCT03124368 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN | ||
| NCT00894075 | Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) | ||
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | ||
| NCT04581785 | Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia | ||
| NCT02496689 | Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) | ||
| NCT00751231 | A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI | ||
| NCT04956276 | Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia | ||
| NCT01567085 | Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor | ||
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | ||
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants | ||
| NCT04609670 | Study of Radiolabeled ALXN2050 in Healthy Adult Males | ||
| NCT02112994 | Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency | ||
| NCT05778071 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism | ||
| NCT04560816 | A Study of the Cardiac Effects of ALXN1840 in Healthy Adults | ||
| NCT00122304 | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab | ||
| NCT03329365 | Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS | ||
| NCT03551743 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4) | ||
| NCT05047458 | A Study of Single-dose ALXN2050 in Healthy Adults | ||
| NCT01095887 | Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation | ||
| NCT02946463 | ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT07024563 | Study of Ravulizumab in Pediatric Participants With Primary IgAN | ||
| NCT00999336 | A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment | ||
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | ||
| NCT06764160 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG | ||
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease | ||
| NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | ||
| NCT03403205 | Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease | ||
| NCT03459443 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 |
